Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Valdecoxib (Bextra)].

A J Scheen1, M Malaise

  • 1Université de Liège.

Revue Medicale De Liege
|June 9, 2004
PubMed
Summary
This summary is machine-generated.

Valdecoxib is a selective COX-2 inhibitor NSAID offering improved gastrointestinal tolerance for osteoarthritis, rheumatoid arthritis, and dysmenorrhea. Its prodrug, parecoxib, is used for postsurgical pain management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes].

Revue medicale de Liege·2008
Same author

[Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].

Revue medicale de Liege·2008
Same author

[Isolated tricuspid valve endocarditis as a cause of fever of unknown origin].

Revue medicale de Liege·2008
Same author

[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].

Revue medicale de Liege·2008
Same author

[Therapy of type 2 diabetes: between insulin sensitizers and insulin secreting agents].

Revue medicale de Liege·2008
Same author

[Aspirin resistance in diabetic patients: laboratory entity or clinical reality?].

Revue medicale de Liege·2007
Same journal

[Nature prescriptions and health promotion : sharing experience from primary care].

Revue medicale de Liege·2026
Same journal

[Eco-health: shared perspectives on primary care practice].

Revue medicale de Liege·2026
Same journal

[The strategic role of primary care in emerging diseases : surveillance, research, and preparedness].

Revue medicale de Liege·2026
Same journal

[Environmental impact of medicines and approaches for more eco responsible use].

Revue medicale de Liege·2026
Same journal

[Climate change and skin].

Revue medicale de Liege·2026
Same journal

[From Silent Spring to neuronal silence : pesticides and neurodegenerative diseases].

Revue medicale de Liege·2026
See all related articles

Area of Science:

  • Pharmacology
  • Drug Development

Context:

  • Valdecoxib is a novel non-steroidal anti-inflammatory drug (NSAID) targeting the COX-2 enzyme.
  • Conventional NSAIDs carry risks of gastrointestinal complications.

Purpose:

  • To introduce valdecoxib as a therapeutic option for inflammatory conditions.
  • To highlight its efficacy and improved gastrointestinal safety profile compared to non-selective NSAIDs.
  • To present its prodrug, parecoxib, for acute pain management.

Summary:

  • Valdecoxib selectively inhibits the COX-2 isoform of cyclo-oxygenase.
  • It is indicated for osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea.
  • Offers comparable efficacy to traditional NSAIDs with enhanced gastrointestinal tolerance.
  • Parecoxib, an injectable prodrug, is available for short-term postsurgical pain relief.

Related Experiment Videos

Impact:

  • Provides a safer alternative for patients requiring NSAID therapy, particularly those at risk for gastrointestinal issues.
  • Expands treatment options for chronic inflammatory diseases and acute pain.
  • Demonstrates the therapeutic potential of selective COX-2 inhibition.